TPWA
REGN icon

Twin Peaks Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$123K Buy
+159
New +$122K 0.03% 250
2025
Q3 		– Sell
-126
Closed -$70.1K – 1647
2025
Q2 		$70.1K Buy
+126
New +$70.3K 0.02% 281

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Twin Peaks Wealth Advisors's REGN Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 159 shares worth $123K. The stake represents 0.03% of the portfolio and ranks #250 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in REGN as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in REGN in Q2 2025 and has held it in 2 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Twin Peaks Wealth Advisors held 159 shares of Regeneron Pharmaceuticals worth $123K as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.03% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #250 holding.
  • Twin Peaks Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.